US FDA approves GSK's oral antibiotic for drug-resistant UTIs
17/06/2026 16:08
US FDA approves GSK's oral antibiotic for drug-resistant UTIs June 17 (Reuters) - The U.S. FDA has approved GSK's GSK.L oral antibiotic to treat complicated urinary tract infections, the regulator said on Wednesday, giving patients a new treatment option against drug-resistant infections.
(Reporting by Sriparna Roy in Bengaluru and Bhanvi Satija in London; Editing by Tasim Zahid)
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)